Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Niels Vande Casteele

    Address9500 Gilman Drive #0956
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology. 2017 Sep; 153(3):835-857.e6. PMID: 28774547.
        View in: PubMed
      2. Vande Casteele N, Khanna R. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res. 2017 Aug; 34(8):1556-1563. PMID: 28374338.
        View in: PubMed
      3. Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 Mar 28. PMID: 28353055.
        View in: PubMed
      4. Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 May; 45(10):1329-1338. PMID: 28318043.
        View in: PubMed
      5. Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Vipul J, Feagan BG. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs. 2017 Mar; 77(4):363-377. PMID: 28233275.
        View in: PubMed
      6. Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG. Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs. 2017 Mar; 77(4):379. PMID: 28247265.
        View in: PubMed
      7. Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 Jan 11. PMID: 28074618.
        View in: PubMed
      8. Van Stappen T, Bollen L, Vande Casteele N, Papamichael K, Van Assche G, Ferrante M, Vermeire S, Gils A. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clin Transl Gastroenterol. 2016 Dec 08; 7(12):e206. PMID: 27929524.
        View in: PubMed
      9. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvenstein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2016 Aug 3. PMID: 27487793.
        View in: PubMed
      10. Ben-Horin S, Casteele NV, Schreiber S, Lakatos P. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. Clin Gastroenterol Hepatol. 2016 May 20. PMID: 27215364.
        View in: PubMed
      11. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 Sep; 14(9):1302-9. PMID: 27189916.
        View in: PubMed
      12. Miligkos M, Papamichael K, Casteele NV, Mantzaris GJ, Gils A, Levesque BG, Zintzaras E. Efficacy and Safety Profile of Anti-Tumor Necrosis Factor-a Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons. Clin Ther. 2016 Apr 16. PMID: 27091732.
        View in: PubMed
      13. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. PMID: 26835982.
        View in: PubMed
      14. Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. J Crohns Colitis. 2016 Sep; 10(9):1015-23. PMID: 27022161.
        View in: PubMed
      15. Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 May; 150(5):1056-60. PMID: 27018491.
        View in: PubMed
      16. Bollen L, Vande Casteele N, Ballet V, van Assche G, Ferrante M, Vermeire S, Gils A. Thromboembolism as an important complication of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016 Jan; 28(1):1-7. PMID: 26513610.
        View in: PubMed
      17. Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. Ann Intern Med. 2016 Jan 5; 164(1):10-22. PMID: 26641955.
        View in: PubMed
      18. Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):543-9. PMID: 26681486.
        View in: PubMed
      19. Bollen L, Vande Casteele N, Peeters M, Van Assche G, Ferrante M, Van Moerkercke W, Declerck P, Vermeire S, Gils A. The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. Inflamm Bowel Dis. 2015 Nov; 21(11):2540-8. PMID: 26313696.
        View in: PubMed
      20. Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015 Nov; 42(10):1158-69. PMID: 26365281.
        View in: PubMed
      21. Vande Casteele N, Vermeire S. High Anti-Tumour Necrosis Factor Trough Concentrations - Only a Cost Issue or Also Hidden Dangers Ahead? J Crohns Colitis. 2015 Nov; 9(11):943-4. PMID: 26351380.
        View in: PubMed
      22. Van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, Gils A. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Sep; 21(9):2172-7. PMID: 26284296.
        View in: PubMed
      23. Vande Casteele N, Sandborn WJ. IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. PMID: 26077557.
        View in: PubMed
      24. Vande Casteele N, Gils A. Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs? Dig Dis Sci. 2015 Sep; 60(9):2571-3. PMID: 25917050.
        View in: PubMed
      25. Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S. Immunogenicity to infliximab is associated with HLA-DRB1. Gut. 2015 Aug; 64(8):1344-5. PMID: 25876612.
        View in: PubMed
      26. Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, Karmiris K, Ferrante M, Gils A, Vermeire S. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2016 Jul; 65(7):1126-31. PMID: 25862647.
        View in: PubMed
      27. Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharmacol. 2015 Mar; 55 Suppl 3:S39-50. PMID: 25707962.
        View in: PubMed
      28. Bollen L, Vande Casteele N, Peeters M, Bessonov K, Van Steen K, Rutgeerts P, Ferrante M, Hoylaerts MF, Vermeire S, Gils A. Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease: A Prospective Study. Inflamm Bowel Dis. 2015 Mar; 21(3):570-8. PMID: 25659086.
        View in: PubMed
      29. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015 Jun; 148(7):1320-1329.e3. PMID: 25724455.
        View in: PubMed
      30. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Casteele NV. Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. PMID: 25222660.
        View in: PubMed
      31. Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1103-10. PMID: 25478919.
        View in: PubMed
      32. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015 Oct; 64(10):1539-45. PMID: 25336114.
        View in: PubMed
      33. Baert F, Vande Casteele N, Tops S, Noman M, Van Assche G, Rutgeerts P, Gils A, Vermeire S, Ferrante M. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014 Dec; 40(11-12):1324-32. PMID: 25277873.
        View in: PubMed
      34. Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, Brouwers E, Vermeire S, Geukens N, Declerck PJ. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014 Oct; 36(5):669-73. PMID: 24906181.
        View in: PubMed
      35. Samaan MA, Bagi P, Vande Casteele N, D'Haens GR, Levesque BG. An update on anti-TNF agents in ulcerative colitis. Gastroenterol Clin North Am. 2014 Sep; 43(3):479-94. PMID: 25110254.
        View in: PubMed
      36. Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, Wolthuis A, Van Assche G, Noman M, Hoffman I, D'Hoore A, Gils A, Rutgeerts P, Ferrante M. A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):531-8. PMID: 25117777.
        View in: PubMed
      37. Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G. Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):514-521.e4. PMID: 25066841.
        View in: PubMed
      38. Vande Casteele N, Sandborn WJ. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1894-6. PMID: 24951843.
        View in: PubMed
      39. Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr; 16(4):378. PMID: 24595615.
        View in: PubMed
      40. Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1474-1481.e2. PMID: 24486408.
        View in: PubMed
      41. Vande Casteele N, Brecx S, Declerck P, Ferrante M, Rutgeerts P, Vermeire S, Gils A. Letter: dry blood spots for anti-TNF treatment monitoring in IBD. Aliment Pharmacol Ther. 2013 May; 37(10):1024-5. PMID: 23590542.
        View in: PubMed
      42. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013 Jun; 108(6):962-71. PMID: 23419382.
        View in: PubMed
      43. Buurman DJ, Vande Casteele N, Sturkenboom MG, Kleibeuker JH, Vermeire S, van der Kleij D, Rispens T, Gils A, Dijkstra G. Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply. Aliment Pharmacol Ther. 2013 Jan; 37(2):282. PMID: 23252783.
        View in: PubMed
      44. Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012 Oct; 36(8):765-71. PMID: 22928581.
        View in: PubMed
      45. Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012 Feb; 61(2):229-34. PMID: 21948942.
        View in: PubMed
      46. Vande Casteele N, Breynaert C, Vermeire S, Rutgeerts PJ, Gils A, Van Assche G. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay. Aliment Pharmacol Ther. 2011 Aug; 34(3):401-3; author reply 404-5. PMID: 21726254.
        View in: PubMed
      47. Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut. 2012 Feb; 61(2):321; author reply 322. PMID: 21330576.
        View in: PubMed
      48. Maertens R, De Canck I, Moraes ME, Vande Casteele N, Van Reybroeck G, Vanderborght B, Moraes JR, Rossau R. Characterization of a new HLA-B39 allele, B*3913, in a Brazilian Caucasian. Tissue Antigens. 1998 Dec; 52(6):583-6. PMID: 9894859.
        View in: PubMed